血脂康联合熊去氧胆酸治疗非酒精性脂肪肝合并高脂血症的效果

Effect of Xuezhikang combined with Ursodeoxycholic Acid in the treatment of non-alcoholic fatty liver with hyperlipidemia

目的探讨血脂康联合熊去氧胆酸治疗非酒精性脂肪肝合并高脂血症的效果。方法选取2021年12月至2022年5月上饶市立医院收治的60例非酒精性脂肪肝合并高脂血症患者作为研究对象,采用随机数字表法将其分为对照组(30例)和观察组(30例)。对照组患者采用熊去氧胆酸治疗,观察组患者采用血脂康+熊去氧胆酸治疗。比较两组患者的治疗总有效率;比较两组患者治疗前后的天冬氨酸转氨酶(AST)、丙氨酸转氨酶(ALT)、总胆红素(TBil)、谷氨酰转肽酶(γ-GT)、总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C);比较两组患者的不良反应总发生率。结果观察组患者的治疗总有效率(93.33%)高于对照组(66.67%),差异有统计学意义(P<0.05)。两组患者治疗前的肝功能指标比较,差异无统计学意义(P>0.05);观察组患者治疗后的AST、ALT、TBil和γ-GT低于对照组,观察组患者治疗后的AST、ALT、TBil和γ-GT低于本组治疗前,差异有统计学意义(P<0.05);对照组患者治疗后的AST、ALT低于本组治疗前,差异有统计学意义(P<0.05);而对照组患者治疗后的γ-GT、Tbil与本组治疗前比较,差异无统计学意义(P>0.05)。两组患者治疗前的血脂指标比较,差异无统计学意义(P>0.05);观察组患者治疗后的TC、TG、LDL-C低于对照组,HDL-C高于对照组,差异有统计学意义(P<0.05);观察组患者治疗后的TC、TG、LDL-C低于本组治疗前,HDL-C高于本组治疗前,差异有统计学意义(P<0.05);对照组患者治疗后的TC、TG、LDL-C低于本组治疗前,差异有统计学意义(P<0.05);对照组患者治疗后的HDL-C与本组治疗前比较,差异无统计学意义(P>0.05)。观察组的不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论应用血脂康+熊去氧胆酸治疗非酒精性脂肪肝合并高脂血症患者的效果显著,能够有效改善患者的脂肪肝和血脂水平,减少不良反应,临床用药安全性高。

Objective To investigate the effect of Xuezhikang combined with Ursodeoxycholic Acid in the treatment of non-alcoholic fatty liver with hyperlipidemia.Methods From December 2021 to May 2022,60 patients with non-alcoholic fatty liver and hyperlipidemia treated in Shangrao Municipal Hospital were selected as the research subjects.They were divided into the control group(30 cases)and the observation group(30 cases)by the random number table method.Participants in the control group were treated with Ursodeoxycholic Acid,and in the observation group,they were treated with Xuezhikang+Ursodeoxycholic Acid.The total effectiveness rate was compared between the two groups.The levels of aspartate aminotransferase(AST),alanine transaminase(ALT),total bilirubin(TBil),glutamyl transpeptidase(γ-GT),total cholesterol(TC),triacylglycerol(TG),low density lipoprotein cholesterol(LDL-C),and high density lipoprotein cholesterol(HDL-C)before and after treatment were compared between the two groups.And the total incidence of adverse reactions was compared between the two groups.Results The total effective rate of observation group(93.33%)was higher than that of control group(66.67%),and the difference was statistically significant(P<0.05).There were no significant differences in liver function indexes between the two groups before treatment(P>0.05).The AST,ALT,TBil andγ-GT of the observation group after treatment were lower than those of the control group,and the AST,ALT,TBil andγ-GT of the observation group after treatment were lower than those before treatment,and the differences were statistically significant(P<0.05).The AST and ALT of the control group after treatment were lower than those before treatment,and the differences were statistically significant(P<0.05).However,there were no significant differences inγ-GT and TBil of the control group after treatment compared with those before treatment(P>0.05).There were no significant differences in blood lipid indexes between the two groups before treatment(P>0.05).After treatment,the TC,TG and LDL-C of the observation group were lower than those of the control group,and the HDL-C of the observation group was higher than that of the control group,and the differences were statistically significant(P<0.05).The TC,TG and LDL-C of the observation group after treatment were lower than those before treatment,and the HDL-C of the observation group after treatment was higher than that before treatment,and the differences were statistically significant(P<0.05).The TC,TG and LDL-C of the control group after treatment were lower than those before treatment,and the differences were statistically significant(P<0.05).There was no significant difference in HDL-C of the control group after treatment compared with that before treatment(P>0.05).The total incidence of adverse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The application of Xuezhikang+Ursodeoxycholic Acid in the treatment of patients with non-alcoholic fatty liver and hyperlipidemia is effective,and can remarkably improves fatty liver and blood lipid levels,reduces adverse reactions,and has high clinical safety.